Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Gout (Chronic Refractory) Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been ...
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Gout - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Gout - Pipeline Insight, 2024," report provides ...
In gout, the drug choices for patients remain limited. The history of this field includes many molecules that fell short in the clinic or on the market for safety reasons. James Mackay knows firsthand ...
(Medical Xpress)—Research at the University of Dundee has shown than an old, inexpensive anti-gout drug has benefits for heart disease sufferers and has the potential to one day help prevent heart ...
Common medicines used to treat gout could also lower the risk of heart attack and stroke, according to a major new study involving more than 100,000 patients. Researchers from the University of ...
Hosted on MSN
NHS gout drug already given to thousands may also prevent deadly heart attacks and strokes
A cheap gout drug may offer hope for thousands of patients with heart issues, promising new research has suggested. German and Swiss scientists tested colchicine on over 10,000 patients with a history ...
A widely used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new review. The work appears in the Cochrane Database of Systematic ...
Drugs that lower uric acid levels in the blood also appear to reduce a person’s risk of heart attack and stroke, researchers reported Jan. 26 in JAMA Internal Medicine. “People with gout are at an ...
For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic ...
Atom’s focus on chronic and acute gout aims to combat a growing worldwide gout threat with few safe and effective existing treatments for patients. Lingdolinurad (ABP-671), a new URAT1 inhibitor, has ...
BANGALORE, June 9 (Reuters) - Regeneron Pharmaceuticals Inc said a late-stage study of its experimental gout drug met the main trial goal of preventing gout attacks, while a second late-stage study ...
October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results